Erratum: Olaparib indication in CRPC guideline Erratum 2 - Abstract added to testis cancer (Can Urol Assoc J (2021) 15:5 (E304) DOI: 10.5489/cuaj.7321)

Abstract

In the guideline entitled, “2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC),” published in the February 2021 issue of CUAJ (Citation: Saad F, Aprikian A, Finelli A, et al. Can Urol Assoc J 2021;15(2):E81-9. http://dx.doi.org/10.5489/cuaj.7074), the correct indication for olaparib should have read as follows: “The Health Canada approval of olaparib is for patients with deleterious or suspected deleterious germline or somatic BRCA1/2 or ATM mutations who have progressed following prior treatment with an NHT (i.e., abiraterone, enzalutamide, apalutamide, darolutamide).” Furthermore, Fig. 1 should have listed olaparib in the mCRPC first-line treatment box with an asterisk indicating, “For patients with HRR mutation and having progressed on an NHT.” CUAJ regrets the oversight and apologizes for any inconvenience. Visit https://cuaj.ca/index.php/journal/article/ view/7074/4792 for a corrected version of the paper.